 |
32 Diseases |  |
9 Trials |
|
9 Trials |  |
795 News |  |
| «12345678910111213» |
- | Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment closed, Trial completion date: TraSki: Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function (clinicaltrials.gov) - Nov 18, 2021
P2, N=16, Active, not recruiting, Sponsor: Prof. Dr. Stephan Weidinger
Recruiting --> Active, not recruiting | Trial completion date: Mar 2022 --> Jul 2022
- lebrikizumab (LY3650150) / Roche, Almirall, Eli Lilly
Lebrikizumab allows (interleukin) IL-13 membrane binding and subsequent internalization through IL-13 receptor alpha 2 (Rα2) [IL-13 decoy receptor] () - Nov 11, 2021 - Abstract #ISDS2021ISDS_188;
In summary, lebrikizumab allows IL13 to bind and internalize through the IL-13Rα2. This mode of action differentiates it from tralokinumab and cendakimab, since lebrikizumab allows natural endogenous regulation of IL-13 levels through IL-13Rα2 (IL13 decoy receptor).
- Adtralza (tralokinumab) / LEO Pharma, AstraZeneca, cendakimab (CC-93538) / AbbVie, BMS, lebrikizumab (LY3650150) / Roche, Almirall, Eli Lilly
Comparison of the affinity and in vitro activity of lebrikizumab, tralokinumab, and cendakimab () - Nov 11, 2021 - Abstract #ISDS2021ISDS_161;
Our data show that, across these monoclonal antibodies, lebrikizumab has the highest affinity and in vitro potency, followed by cendakimab, and then tralokinumab. Overall, lebrikizumab binds human IL-13 with high affinity and neutralizes its functional activity with high potency, providing insight to the clinical efficacy seen by lebrikizumab in Phases 2b and 3 atopic dermatitis studies.
- Comparative effectiveness of targeted therapies with topical corticosteroids for moderate-to-severe atopic dermatitis: Systematic review and network meta-analysis () - Nov 11, 2021 - Abstract #ISDS2021ISDS_160;
Seven placebo-controlled trials encompassing 3453 patients across five targeted therapies (abrocitinib, baricitinib, dupilumab, tralokinumab, upadacitinib) were included. Among targeted therapies used with concomitant TCS, upadacitinib 30 mg was the most efficacious for moderate-to-severe AD, followed by abrocitinib 200 mg, upadacitinib 15 mg, and dupilumab.
- Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
Long-term treatment with tralokinumab normalizes the molecular gene signature of atopic dermatitis () - Nov 11, 2021 - Abstract #ISDS2021ISDS_126;
P3
At 2 years, tralokinumab treatment also modified the transcriptomic profile of the non-lesional skin, improving the subclinical disease seen at baseline in normal-appearing skin. These shifts in the cutaneous biomarker profile highlight the role of IL-13 as a key driver of the AD molecular signature, and support the role of targeted biologic therapy for long-term AD management.
- Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
Histopathological analysis of ECZTRA 1 study revealed the reduction of innate lymphoid cells in skin of atopic dermatitis patients after tralokinumab treatment () - Nov 11, 2021 - Abstract #ISDS2021ISDS_125;
P3
Overall, our study suggests that ILCs respond to IL-13 and that treatment with tralokinumab leads to a reduced ILCs infiltration in lesional skin. This provides insights into the mechanism of how IL-13 modulates the pathophysiology of AD.
- Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with tralokinumab () - Nov 11, 2021 - Abstract #ISDS2021ISDS_124;
P3
The biomarker signature p-EASI correlated with disease severity in moderate-severe AD patients treated with tralokinumab in a clinical trial setting. The use of objective biomarkers such as p-EASI may be considered as a tool to objectively assess treatment effect of new drugs for AD.
- Adtralza (tralokinumab) / LEO Pharma, AstraZeneca, lebrikizumab (LY3650150) / Roche, Almirall, Eli Lilly, Dupixent (dupilumab) / Sanofi, Regeneron
IL-13 and IL-4 promote proliferation and mRNA expression of MUC2 and MUC5AC in primary human conjunctival goblet cells () - Nov 11, 2021 - Abstract #ISDS2021ISDS_39;
As CGCs are essential for maintaining homeostasis of the conjunctival mucosal surface, our findings may at least in part provide a mechanistic explanation behind the ophthalmological adverse events observed after treatment with biologics inhibiting IL-4 and IL-13 signaling. Due to the functional redundancy of IL-13 and IL-4 on CGC biology, targeted treatment with monoclonal antibodies that specifically neutralize IL-13 might be associated with a lower incidence of conjunctivitis in AD patients compared to inhibiting both IL-13 and IL-4 with dupilumab.
- || Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
Review, Journal: Tralokinumab in atopic dermatitis. (Pubmed Central) - Nov 11, 2021
Tralokinumab was significantly superior to placebo regarding the proportion of patients achieving IGA 0/1 and EASI-75 at week 16 (primary endpoints), as well as improving scores for worst daily pruritus, Dermatology Life Quality Index (DLQI), and Scoring Atopic Dermatitis (SCORAD) (secondary endpoints). The week 16 response was sustained during follow-up, and treatment with tralokinumab was found to be well-tolerated with an overall frequency and severity of adverse events comparable to placebo.
- || Xolair (omalizumab) / Roche, Novartis
Biomarker, Review, Journal: Effect of monoclonal antibody drug therapy on mucosal biomarkers in airway disease: a systematic review. (Pubmed Central) - Nov 4, 2021
An understanding of the biological effect is essential to identify likely responders, reasons for treatment failure and necessary adjustments to monoclonal antibody treatment. Further investigation into the effect of monoclonal antibody therapy on disease mucosa and more precise endotyping are required to move closer to achieving personalized medicine.
- || Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
Review, Journal: Tralokinumab bei atopischer Dermatitis. (Pubmed Central) - Oct 22, 2021
Further investigation into the effect of monoclonal antibody therapy on disease mucosa and more precise endotyping are required to move closer to achieving personalized medicine. No abstract available
- ||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment closed: Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND (clinicaltrials.gov) - Oct 18, 2021
P3, N=1600, Active, not recruiting, Sponsor: LEO Pharma
No abstract available Enrolling by invitation --> Active, not recruiting
- || Xolair (omalizumab) / Roche, Novartis
Review, Journal: Biologics for Atopic Dermatitis. (Pubmed Central) - Oct 6, 2021
Dupilumab has been approved for patients 6 years of age and older with moderate to severe AD. Monoclonal antibodies are in phase 3 trials and may become part of a precision medicine approach to AD.
- | Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
Dermatite atopica, a #EADV2021 @LEOPharmaIt presenta i nuovi dati di tralokinumab - Cronache di Scienza - https://t.co/oMbuXywYJP (Twitter) - Oct 5, 2021
- | Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
Dermatite atopica, i nuovi dati di tralokinumab nella terapia continuativa #EDVCONGRESS #EADV21 https://t.co/aLMNWqAIBl (Twitter) - Sep 30, 2021
- | Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
@LEOPharma presenta nuevos datos de seguimiento de Adtralza® (tralokinumab) tras un tratamiento continuo a largo plazo en el 30° Congreso #EADV #salud #pacientes @alsoldelacosta @cuquita1982 #PiscisComunicacion (Twitter) - Sep 30, 2021
- Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
[VIRTUAL] Updates on COVID-19 cases and SARS-CoV-2 vaccinations during tralokinumab treatment in moderate-to-severe atopic dermatitis from ECZTEND long-term extension trial () - Sep 24, 2021 - Abstract #EADV2021EADV_1744;
- Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
[VIRTUAL] Predictors of maintained response with tralokinumab every four weeks dosing in adults with moderate-to-severe atopic dermatitis (Room 1) - Sep 21, 2021 - Abstract #EADV2021EADV_1359;
- Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
[VIRTUAL] Two-year maintenance of response with tralokinumab in moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial (Room 13) - Sep 21, 2021 - Abstract #EADV2021EADV_1293;
- || cyclosporine / Generic mfg.
Review, Journal: A new era has begun: Treatment of atopic dermatitis with biologics. (Pubmed Central) - Sep 18, 2021
In addition to antibody-based therapies, "small molecules" that, e.g., inhibit Janus kinases enrich the armamentarium of systemic AD therapies. With all these agents, not only will many more targeted therapies become available, but also will the complex and heterogeneous pathophysiological processes of this disease be better understood.
- ||||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Trial completion, Combination therapy: ECZTRA 8: Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis (clinicaltrials.gov) - Sep 9, 2021
P3, N=126, Completed, Sponsor: LEO Pharma
With all these agents, not only will many more targeted therapies become available, but also will the complex and heterogeneous pathophysiological processes of this disease be better understood. Active, not recruiting --> Completed
- || Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
Clinical, Journal: Tralokinumab Does Not Impact Vaccine-induced Immune Responses: Results From a 30-week, Randomized, Placebo-controlled Trial in Adults With Moderate-to-severe Atopic Dermatitis. (Pubmed Central) - Sep 1, 2021
P2
Treatment with tralokinumab 300 mg every 2 weeks did not affect immune responses to Tdap and meningococcal vaccines. Treatment was well tolerated when administered concomitantly with the vaccines and demonstrated a safety profile comparable to phase 3 trials.
- || Retrospective data, Review, Journal: Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. (Pubmed Central) - Aug 26, 2021
In monotherapy and combination therapy RCTs, the probability of treatment-emergent adverse events (TEAEs) was higher among all active treatments than with placebo (except for dupilumab 300 mg Q2W [odds ratio (OR), 0.96; 95% credible interval (CrI), 0.45-2.18] and abrocitinib 100 mg QD [OR, 0.95; 95% CrI, 0.35-2.66] in combination therapy RCTs), although active treatments did not significantly differ from one another. Abrocitinib, dupilumab, and upadacitinib were consistently the most effective systemic therapies in adult and adolescent patients with AD, with no significant TEAE differences in short-term RCTs.
- || cyclosporine / Generic mfg.
Review, Journal: What's new in atopic eczema? An analysis of systematic reviews published in 2018. Part 2: systemic therapies. (Pubmed Central) - Jul 30, 2021
Biologic therapies in AE treatment are being increasingly investigated, and to date, the greatest quantity of data and evidence of efficacy relates to dupilumab...Other biologics showing some evidence of efficacy include nemolizumab, lebrikizumab and tralokinumab, although further data are needed...A Cochrane review on probiotics showed no significant benefit, and SRs and meta-analyses on complementary and alternative medicines, including probiotics, in paediatric AE demonstrated significant heterogeneity, thereby limiting their interpretation. This summary of recent SRs provides up-to-date evidence for clinicians on systemic therapies in AE.
- || Xolair (omalizumab) / Roche, Novartis
Review, Journal: Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis. (Pubmed Central) - Jul 28, 2021
Phase II trials of GBR 830 and KHK 4083 are ongoing. In general, further studies are needed to explore new therapeutic targets and improve the efficacy of biological agents.
- Dupixent (dupilumab) / Sanofi, Regeneron
[VIRTUAL] A computational model suggested potential therapies for dupilumab poor responders in atopic dermatitis () - Jul 8, 2021 - Abstract #ESDR2021ESDR_132;
The model will serve as a computational platform for model-informed drug development for precision medicine, as it allows to evaluate the validity of potential drug targets, including combinations of multiple targets, in stratified patients. Similar mathematical models and simulation can be also applicable for other diseases and therapies when there are reported clinical efficacies of multiple drugs.
- | Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
Preclinical, Journal: Skin Barrier and Inflammation Genes Associated with Atopic Dermatitis are Regulated by Interleukin-13 and Modulated by Tralokinumab In vitro. (Pubmed Central) - Jul 3, 2021
Similar mathematical models and simulation can be also applicable for other diseases and therapies when there are reported clinical efficacies of multiple drugs. No abstract available
- Adtralza (tralokinumab) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron
[VIRTUAL] Efficacy and safety of tralokinumab plus topical corticosteroids in patients with severe atopic dermatitis and prior history of dupilumab treatment: a post hoc subgroup analysis from ECZTRA 7 trial () - Jun 29, 2021 - Abstract #RAD2021RAD_69;
P3
Overall frequencies of adverse events in dupilumabexperienced patients treated with tralokinumab + TCS as needed were consistent with the pooled analysis of tralokinumab Phase 2 and 3 trials. 1 Due to the small sample size, further studies involving more patients are needed to confirm these findings.
- Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
[VIRTUAL] Rapid and sustained improvements in itch and sleep with tralokinumab treatment in patients with moderate-to-severe Atopic Dermatitis, a post hoc analysis of pooled data from ECZTRA 1 and 2 () - Jun 29, 2021 - Abstract #RAD2021RAD_68;
P3
1 Due to the small sample size, further studies involving more patients are needed to confirm these findings. Tralokinumab monotherapy showed rapid and sustained improvements from baseline in itch and sleep interference relative to placebo, starting from Day 2 after the first dose.
- Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
[VIRTUAL] Long-term improvements observed in tralokinumab-treated patients with moderate-to-severe atopic dermatitis: an ECZTEND interim analysis () - Jun 29, 2021 - Abstract #RAD2021RAD_40;
P3
Tralokinumab monotherapy showed rapid and sustained improvements from baseline in itch and sleep interference relative to placebo, starting from Day 2 after the first dose. These data support the effectiveness of tralokinumab in leading to long-term improvements; tralokinumab is well-tolerated in patients with moderate-to-severe AD.
- Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
[VIRTUAL] Impact of targeting interleukin-13 on Staphylococcus aureus colonization: results from a Phase 3, randomized, double-blind, placebo-controlled trial with tralokinumab in adult patients with atopic dermatitis () - Jun 29, 2021 - Abstract #RAD2021RAD_39;
P3
This supports previous studies (Guttman-Yassky E, et al. Presented at: EADV, Paris, France; Poster P0283; 2018) and suggests that reduction of S. aureus colonization by neutralization of IL-13 contributes to the efficacy of tralokinumab in improving the hallmarks of atopic dermatitis and breaking the cycle of itching, scratching, skin barrier dysfunction, and immune-mediated inflammation.
- Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
[VIRTUAL] Neutralizing interleukin-13 increases skin microbial diversity: results from a Phase 3, randomized, double-blind, placebo-controlled trial of tralokinumab in adult patients with atopic dermatitis () - Jun 29, 2021 - Abstract #RAD2021RAD_38;
P3
The increase in skin microbial diversity observed with tralokinumab treatment supports the notion that neutralization of IL-13 contributes to improving the hallmarks of atopic dermatitis by breaking the cycle of itching, scratching, skin barrier dysfunction, and immunemediated inflammation, thereby shifting the microbial diversity on atopic dermatitis lesional skin towards a commensal flora. It remains to be elucidated whether the lack of microbial diversity in atopic dermatitis is a net result of an epidermal barrier defect or a cause of barrier dysfunction and inflammation.
- Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
[VIRTUAL] Neutralizing interleukin-13 with tralokinumab shifts the molecular phenotype of lesional skin towards that of non-lesional skin and restores skin barrier abnormalities () - Jun 29, 2021 - Abstract #RAD2021RAD_37;
Conclusion. Our analysis showed that treatment with tralokinumab shifted the transcriptome of lesional skin towards that of non-lesional skin, demonstrating that specific neutralization of the IL-13 cytokine is able to reverse key AD skin abnormalities.
- || Review, Journal: Innovation in Atopic Dermatitis: From Pathogenesis to Treatment. (Pubmed Central) - Jun 26, 2021
g., baricitinib, upadacitinib, and abrocitinib)...In this article, we review the main advances in the treatment of atopic dermatitis. Characterization of clinical and molecular phenotypes with a key pathogenic role is essential for driving these advances.
- Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
[VIRTUAL] Safety of specifically targeting interleukin-13 with tralokinumab in adult patients with moderatetosevere atopic dermatitis: pooled analysis of five randomized, doubleblind, placebocontrolled trials () - Jun 23, 2021 - Abstract #SDDS2021SDDS_57;
- Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
[VIRTUAL] Tralokinumab provides progressive improvements beyond week 16 in patients with atopic dermatitis who have an initial partial response () - Jun 23, 2021 - Abstract #SDDS2021SDDS_56;
- Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
[VIRTUAL] Early and sustained improvements in patient-reported outcomes with tralokinumab plus topical corticosteroids in moderate-to-severe atopic dermatitis () - Jun 23, 2021 - Abstract #SDDS2021SDDS_55;
- Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
[VIRTUAL] Progressive and sustained improvements in extent and severity of atopic dermatitis in patients with moderate-to-severe disease treated with tralokinumab plus topical corticosteroids as needed () - Jun 23, 2021 - Abstract #SDDS2021SDDS_54;
- Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
[VIRTUAL] Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two Phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2) () - Jun 11, 2021 - Abstract #RAD2021RAD_28;
In patients with moderate-to-severe atopic dermatitis treated with tralokinumab monotherapy, the initial response to tralokinumab was maintained at high levels at week 52 without topical corticosteroid use and was well tolerated. Step-down to q4w dosing may be an option for some patients.
- [VIRTUAL] Comparison of Efficacy of Targeted Therapies without Topical Corticosteroids for Moderate to severe Atopic Dermatitis: Systematic Review and Network Meta-analysis () - Jun 11, 2021 - Abstract #RAD2021RAD_26;
P3
When including the upadacitinib trials, the NMA analyzed 11 unique placebo-controlled trials encompassing 6,254 patients in 28 arms across five targeted therapies (abrocitinib, baricitinib, dupilumab, tralokinumab, upadacitinib). Among targeted therapies used as monotherapy without concomitant TCS, upadacitinib 30mg appears to be the most efficacious treatment for patients with moderate to severe AD, followed by abrocitinib 200mg, upadacitinib 15mg, and dupilumab.
- Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
[VIRTUAL] COVID-19 in tralokinumab-treated patients with moderate-to-severe atopic dermatitis: case series from the ECZTEND long-term extension trial () - Jun 11, 2021 - Abstract #RAD2021RAD_25;
The recent ECZTRA 5 vaccine study showed that non-live vaccines could be safely administered and can elicit normal immune responses in patients treated with tralokinumab. 1 In the present study, COVID-19 cases were predominately mild or moderate (96%), and all patients continued tralokinumab treatment following COVID-19 diagnosis.
- Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
[VIRTUAL] Tralokinumab: What is it and how should we use it? () - Jun 11, 2021 - Abstract #RAD2021RAD_18;
- ||| Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
Clinical, P3 data, Journal: Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). (Pubmed Central) - Jun 3, 2021
P3
1 In the present study, COVID-19 cases were predominately mild or moderate (96%), and all patients continued tralokinumab treatment following COVID-19 diagnosis. Tralokinumab monotherapy was superior to placebo at 16 weeks of treatment and was well tolerated up to 52 weeks of treatment.
- ||| Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
Clinical, P3 data, Journal: Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. (Pubmed Central) - Jun 3, 2021
Tralokinumab monotherapy was superior to placebo at 16 weeks of treatment and was well tolerated up to 52 weeks of treatment. Tralokinumab 300 mg in combination with TCS as needed was effective and well tolerated in patients with moderate-to-severe AD.
- | Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
Journal: Tralokinumab for atopic dermatitis: a promising new therapy. (Pubmed Central) - Jun 3, 2021
Tralokinumab 300 mg in combination with TCS as needed was effective and well tolerated in patients with moderate-to-severe AD. No abstract available
- Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
[VIRTUAL] Efficacy and safety of tralokinumab in a United States subpopulation of patients with moderate-to-severe atopic dermatitis: a subanalysis of ECZTRA 1 and 2, two phase 3, randomized, double-blinded, placebo-controlled trials () - May 29, 2021 - Abstract #SBS2021SBS_166;
P3
No abstract available Tralokinumab 300 mg q2w demonstrated improvements in the signs and symptoms of moderate-to-severe atopic dermatitis, with a good safety profile, in a pooled analysis of a diverse US subpopulation in ECZTRA 1 and 2 studies.
- Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
[VIRTUAL] Efficacy and safety of tralokinumab in a United States subpopulation of patients with moderate-to-severe atopic dermatitis: a subanalysis of ECZTRA 3, a phase 3, randomized, double-blind, placebo-controlled study () - May 29, 2021 - Abstract #SBS2021SBS_165;
P3
Tralokinumab 300 mg q2w plus TCS improved signs and symptoms of moderate‐ to‐severe AD, with good safety in post hoc analysis of the ECZTRA 3 US subpopulation. Despite this subpopulation being among the most diverse groups in the study for baseline characteristics, tralokinumab plus TCS showed superior efficacy and similar safety to placebo plus TCS.
- | Journal: Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect. (Pubmed Central) - May 25, 2021
Dupilumab is the only biologic therapy that is Food and Drug Administration approved for the treatment of moderate-to-severe AD in patients 6 years and older, with consistent long-term efficacy and safety trial data. In this article, we review the mechanisms, safety, and efficacy of dupilumab from recent clinical trials, and we review the current data, mechanism of action, clinical efficacy, and limitations of new biologics currently in phase 2 and 3 clinical trials (lebrikizumab, tralokinumab, nemolizumab, tezepelumab, and ISB 830).
- || Adtralza (tralokinumab) / LEO Pharma, AstraZeneca
Clinical, P2b data, Journal, HEOR: Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitisA phase 2b randomized study. (Pubmed Central) - May 20, 2021
P2b
In this article, we review the mechanisms, safety, and efficacy of dupilumab from recent clinical trials, and we review the current data, mechanism of action, clinical efficacy, and limitations of new biologics currently in phase 2 and 3 clinical trials (lebrikizumab, tralokinumab, nemolizumab, tezepelumab, and ISB 830). No abstract available
- || Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment closed: A Trial to Compare the Pharmacokinetics of Tralokinumab in Healthy Subjects (clinicaltrials.gov) - May 19, 2021
P1, N=106, Active, not recruiting, Sponsor: LEO Pharma
No abstract available Not yet recruiting --> Active, not recruiting